However, for CD28’s inhibitory counter player CTLA-4 it has been shown that the 49G polymorphism, leading to comparatively weak B7-binding (55), is associated with enhanced T cell responses in vitro (55, 56) and a higher risk to develop chronic GvHD in vivo (57). Here, CTLA4 is linked to chronic graft versus host disease.